https://www.selleckchem.com/pr....oducts/oxalacetic-ac
Anti-GBM disease is a life-altering adverse event that can be associated with alemtuzumab. Our case highlights the limitations of monitoring urinalyses as a trigger for anti-GBM antibody testing in patients who have received alemtuzumab and have baseline abnormal urinalyses; such patients may require further protocolized anti-GBM antibody testing, although the optimal frequency of such antibody screening remains unclear. Anti-GBM disease is a life-altering adverse event that can be associated with alemtuzumab. Our case highlight
Like
Comment
Share
